must be received not later than December 20, 2004.

A. Federal Reserve Bank of Atlanta
(Sue Costello, Vice President) 1000 Peachtree Street, N.E., Atlanta, Georgia 30303:

1. Rogers Investments, LP, Russellville, Alabama, with Dianne Rogers Barnes, Marietta, Georgia, and Robert Isaac Rogers, Jr., Russellville, Alabama, as general partners; Rogers Family Holdings, LLC, Russellville, Alabama, with Dianne Rogers Barnes and Robert Isaac Rogers, Jr., as managers, and whose members include the two managers and Anne C. Rogers, Russellville, Alabama, the R.I. Rogers, Sr. Marital Trust GST Non—Exempt, the Robert I. Rogers, Sr. GST Exempt Family Trust, and the Robert I. Rogers, Sr. Marital Trust GST Exempt, with Robert Isaac Rogers, Jr., and Dianne Rogers Barnes serving as trustees of the trusts; and Robert Isaac Rogers, Jr., and Dianne Rogers Barnes; to collectively retain voting shares of Valley State Bank, both of Russellville, Alabama, and Robert I. Rogers, Sr., Marital Trust GST Exempt, with Robert Isaac Rogers, Jr., and Dianne Rogers Barnes serving as trustees of the trusts; and Robert Isaac Rogers, Jr., and Dianne Rogers Barnes; to collectively retain voting shares of Valley Bancshares, Inc., Rogers Barnes; to collectively retain voting shares of Valley State Bank, both of Russellville, Alabama, and the Robert I. Rogers, Sr. GST Exempt Family Holdings, LLC, Russellville, California 94105—1579:

1. Great Western Bancorp, Inc., Phoenix, Arizona: to become a bank holding company by acquiring at least 45 percent of the voting shares of Western National Bank, Phoenix, Arizona (in organization).


Robert deV. Frierson,
Deputy Secretary of the Board.

A. Federal Reserve Bank of San Francisco (Tracy Basinger, Director, Regional and Community Bank Group) 101 Market Street, San Francisco, California 94105—1579:

1. Great Western Bancorp, Inc., Phoenix, Arizona: to become a bank holding company by acquiring at least 45 percent of the voting shares of Western National Bank, Phoenix, Arizona (in organization).


Robert deV. Frierson,
Deputy Secretary of the Board.

FOR FURTHER INFORMATION CONTACT:
Lauren Lambert, Centers for Disease Control and Prevention, National Center for HIV, STD, and TB Prevention, 1600 Clifton Road, NE., Mailstop E10, Atlanta, Georgia 30333. Telephone: (404) 639—8120. Email: TBinfectioncontrol@cdc.gov.

SUPPLEMENTARY INFORMATION: As stated above, the 2005 draft Guidelines reflect shifts in the epidemiology of tuberculosis, advances in scientific understanding, and changes in healthcare practice that have occurred in the United States in the last decade. In the context of diminished risk of healthcare-associated transmission of *M. tuberculosis*, the 2005 Draft Guidelines places emphasis on actions needed to maintain momentum and expertise needed to avert another resurgence of tuberculosis and to eliminate the lingering threat to healthcare workers, which is mainly from patients or others with unsuspected and undiagnosed infectious tuberculosis disease. Whereas previous Guidelines were aimed primarily at hospital-based facilities, the 2005 CDC Guidelines have been expanded to address a broader concept: healthcare-associated settings go beyond the previously defined facilities.
CDC expects to publish final Guidelines in 2005.


James D. Seligman, Associate Director for Program Services, Centers for Disease Control and Prevention (CDC).

[FR Doc. 04–26710 Filed 12–3–04; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2004N–0395]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Application for Participation in the Medical Device Fellowship Program

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.


Jeffrey Shuren, Assistant Commissioner for Policy.

[FR Doc. 04–26672 Filed 12–3–04; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Request for Nominations for a Nonvoting Member Representing Industry Interests on a Public Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) requests nominations for a nonvoting industry representative to serve on the Cellular Tissue and Gene Therapies Advisory Committee (formerly the Biological Response Modifiers Advisory Committee) under the purview of the Center for Biologics Evaluation and Research (CBER).


Jeffrey Shuren, Assistant Commissioner for Policy.

[FR Doc. 04–26672 Filed 12–3–04; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[FR Doc. 04–26672 Filed 12–3–04; 8:45 am]

BILLING CODE 4160–01–S